Suresh Nair

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations · Full text

Checkmate 063, Single-arm Trial, Medicine +8

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

Qihong Huang, Kiranmai Gumireddy, Mariëtte Schrier et al. · Nature Cell Biology · 2008 · 962 citations

Oncology, Medicine, Microrna Detection +7

Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

Steven R. Alberts, William L. Horvath, William C. Sternfeld et al. · Journal of Clinical Oncology · 2005 · 534 citations · Full text

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan et al. · The Lancet Oncology · 2016 · 329 citations · Full text

Medicine, Melanoma, Clinical Trials +8